摘要:
A granular enzyme composition is produced having reduced tendency to form dust and leave a residue, and improved stability and delayed release characteristics. The composition has a core, optionally coated with a vinyl polymer, a layer containing an enzyme and a vinyl polymer and optionally a plasticizer or anti-agglomeration agent, and an outer coating containing a polymer and optionally a low residue pigment and/or lubricant. Preferably, the core is a salt or sugar nonpareil, the vinyl polymer coating the core is polyvinyl alcohol and most preferably partially hydrolyzed polyvinyl alcohol, the vinyl polymer in the enzyme layer is polyvinyl pyrrolidone, and the polymer of the outer coating is polyvinyl pyrrolidone, polyvinyl alcohol which may be partially hydrolyzed, polyethylene glycol or mixtures thereof such as a mixture of polyvinyl pyrrolidone and polyvinyl alcohol or a mixture of polyvinyl pyrrolidone and polyethylene glycol. Preferably, the pigment is titanium dioxide and the lubricant is a nonionic or anionic surfactant such as a linear primary alcohol of a 9-15 carbon atom chain length alkane or alkene or an ethoxylate or ethoxysulfate derivative thereof. The enzyme can be a protease, amylase, lipase, cellulase, xylanase, oxidase, peroxidase or mixtures thereof. The composition may be produced by spray coating in a fluidized bed a solution of the enzyme and vinyl polymer onto the core to form the enzyme layer, and then spray coating in a fluidized bed a solution of polymer on the enzyme layer to form the outer coating.
摘要:
A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).
摘要:
Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.
摘要:
An implantable medical device including a polymer matrix containing everolimus and pimecrolimus, and methods of using the device for the treatment of vascular disease are disclosed.
摘要:
Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.
摘要:
Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.
摘要:
A composite implantable device for promoting tissue ingrowth therein comprising a biodurable reticulated elastomeric matrix having a three-dimensional porous structure having a continueous network of interconnected and intercommunicating open pores and a support structure is disclosed. The support structure may be a polymeric surgical mesh comprising a plurality of intersecting one-dimensional reinforcement elements, wherein said mesh is affixed to a face of said first matrix. Methods of making and using the implantable device are also provided.
摘要:
Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.
摘要:
A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).